Science News
from research organizations

Combination Antiretroviral Therapy Effective At Reducing HIV Resistance In Mothers And Babies Following Mother-to-child Transmission

Date:
October 28, 2009
Source:
Public Library of Science
Summary:
In a clinical trial investigating mother-to-child HIV transmission in South Africa researchers find that adding two other antiretroviral drugs to single dose nevirapine -- an antiretroviral drug given to women and newborn children during labor and delivery to prevent transmission -- is effective in reducing the drug resistance that nevirapine causes when used by itself.
Share:
       
FULL STORY

In a clinical trial investigating mother-to-child HIV transmission in South Africa published this week in PLoS Medicine, Neil Martinson (of the Perinatal HIV Research Unit, Soweto, South Africa) and colleagues find that adding two other antiretroviral drugs to single dose nevirapine -- an antiretroviral drug given to women and newborn children during labor and delivery to prevent transmission -- is effective in reducing the drug resistance that nevirapine causes when used by itself.

Such resistance can compromise later treatment regimens that include the same class of drug as nevirapine. The researchers report that the combination drug regimen -- which involved the addition of a twice-daily dose of zidovudine and lamivudine over several days following a single-dose of nevirapine -- is safe and easy to provide, and effective in reducing subsequent nevirapine resistance in both mothers and those babies that are infec ted despite antiretrovirals.

In a related Perspective, Dara Lehman (of Fred Hutchinson Cancer Research Center, Seattle, Washington) and colleagues, uninvolved with the research, say that assuming that there is not a large amount of lurking resistance not detected by the study, the approach may "strike the right balance of a feasible regimen that minimizes resistance" in resource-poor settings where combination antiretroviral therapy may not be available for longer-term use in pregnancy.

Funding: Boehringer Ingelheim, the developer and manufacturer of nevirapine, funded this trial, designed the study, was involved in data collection, and was responsible for data management and involved in the analysis. The decision to publish and preparation of the manuscript included employees of the sponsor, which gave an assurance that all authors have full access to the trial dataset.

Competing interests: M. Hopley, M. Ekelund, D. B. Hall, and P. Robinson are employed by Boehringer Ingelheim, the sponsor of the study, and D. Mayers was employed by Boehringer Ingelheim at the time of the study.


Story Source:

The above post is reprinted from materials provided by Public Library of Science. Note: Materials may be edited for content and length.


Journal Reference:

  1. McIntyre et al. Efficacy of Short-Course AZT Plus 3TC to Reduce Nevirapine Resistance in the Prevention of Mother-to-Child HIV Transmission: A Randomized Clinical Trial. PLoS Medicine, 2009; 6 (10): e1000172 DOI: 10.1371/journal.pmed.1000172

Cite This Page:

Public Library of Science. "Combination Antiretroviral Therapy Effective At Reducing HIV Resistance In Mothers And Babies Following Mother-to-child Transmission." ScienceDaily. ScienceDaily, 28 October 2009. <www.sciencedaily.com/releases/2009/10/091026220007.htm>.
Public Library of Science. (2009, October 28). Combination Antiretroviral Therapy Effective At Reducing HIV Resistance In Mothers And Babies Following Mother-to-child Transmission. ScienceDaily. Retrieved August 30, 2015 from www.sciencedaily.com/releases/2009/10/091026220007.htm
Public Library of Science. "Combination Antiretroviral Therapy Effective At Reducing HIV Resistance In Mothers And Babies Following Mother-to-child Transmission." ScienceDaily. www.sciencedaily.com/releases/2009/10/091026220007.htm (accessed August 30, 2015).

Share This Page: